



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.
9516-072-999

APPLICATION NO
10/411,649


APPLICANT
Zeldis

FILING DATE
April 11, 2003

GROUP
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
W	A01	60/372,348	6/2002	Hariri et al. 9516-046-888			4/12/02
	A02	US 2003/0096841	5/22/03	Robarge et al.			12/21/01
	A03	US 2003/0045552	3/6/03	Robarge et al.			10/5/01
	A04	US 2002/0045643	4/18/02	Muller et al.			2/12/01
	A05	6,476,052	11/5/02	Muller et al.			
	A06	6,395,754	5/28/02	Muller et al.			
	A07	6,335,349	1/1/02	Muller et al.			
	A08	6,316,471	11/13/01	Muller et al.			
	A09	6,281,230	8/28/01	Muller et al.			
	A10	6,071,948	6/6/00	D'Amato			
	A11	5,929,117	7/27/99	Muller et al.			
	A12	5,877,200	3/2/99	Muller			
	A13	5,874,448	2/23/99	Muller et al.			
	A14	5,798,368	8/25/98	Muller et al.			
	A15	5,733,566	3/31/98	Lewis			
	A16	5,698,579	12/16/97	Muller			
	A17	5,674,533	10/7/97	Santus et al.			
	A18	5,643,915	7/1/97	Andrulic et al.			
	A19	5,639,476	6/17/97	Oshlack et al.			
	A20	5,635,517	6/3/97	Muller et al.			
	A21	5,629,327	5/13/97	D'Amato			
	A22	5,593,990	1/14/97	D'Amato			
	A23	5,591,767	1/7/97	Mohr et al.			
	A24	5,580,755	12/3/96	Souza			
	A25	5,528,823	6/25/96	Rudy et al.			
	A26	5,393,870	2/28/95	Deeley et al.			
	A27	5,391,485	2/21/95	Deeley et al.			
	A28	5,354,556	10/11/94	Sparks et al.			
	A29	5,229,496	7/20/93	Deeley et al.			
	A30	5,134,127	7/28/92	Stella et al.			
	A31	5,120,548	6/9/92	McClelland et al.			
	A32	5,073,543	12/17/91	Marshall et al.			
	A33	5,059,595	10/22/91	LeGrazie			
	A34	4,999,291	3/12/91	Souza			
	A35	4,810,643	3/7/89	Souza			
W	A36	4,008,719	2/22/77	Theeuwes et al.			




A37 A38 A39 A40	3,916,899						
	3,845,770						
	3,598,123						
	3,536,809						

FOREIGN PATENT DOCUMENTS


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
B01	WO 02/059106	8/1/02	PCT				
B02	WO 01/87307	11/22/01	PCT				
B03	WO 01/87306	11/22/01	PCT				
B04	WO 98/54170	12/3/98	PCT				
B05	WO 98/03502	1/29/98	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Bezley et al., 1985, "Malignant stricture at the confluence of the biliary tree: diagnosis and management," <i>Surg. Annu.</i> 17:125-41
C02	Bennett et al., 1985, "Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group," <i>Ann. Intern. Med.</i> 103(4):620-625
C03	Besa, 1992, "Myelodysplastic syndromes (refractory anemia). A perspective of the biologic, clinical, and therapeutic issues," <i>Med. Clin. North Am.</i> 76(3):599-617
C04	Besa et al., 1990, 76(Supp. 1):133a
C05	Bowen et al., 1991, "The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin," <i>Br. J. Haematol.</i> 71(3):419-423
C06	Cartensen, 1995, <i>Drug Stability: Principles & Practice</i> , 2nd ed., Marcel Dekker, New York, NY pp. 379-380
C07	Corral et al., 1999, <i>Ann. Rheum. Dis.</i> 58(Supp. 1):1107-1113
C08	Costa et al., 1998, <i>Blood</i> 92(10:suppl. 1):235b, Abstract #4007
C09	D'Amato et al., 1994, "Thalidoide is an inhibitor of angiogenesis," <i>PNAS USA</i> 91(9):4082-4085
C10	Dexter, 1989, "Haemopoietic growth factors," <i>Br. Med. Bull.</i> 45(2):337-349
C11	Dexter, 1987, "Growth factors involved in haemopoiesis," <i>J. Cell. Sci.</i> 88 (Pt 1):1-6
C12	Dredge et al., 2002, "Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects," <i>Br. J. Cancer</i> 87(10):1166-1172
C13	Ehrenpreis et al., 1999, "Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial," <i>Gastroenterology</i> 117(6):1271-1277
C14	Emens et al., 2001, "Chemotherapy: friend or foe to cancer vaccines?" <i>Curr. Opin. Mol. Ther.</i> 3(1):77-84
C15	Golde et al., 1988, "Hormones that stimulate the growth of blood cells," <i>Sci. Am.</i> 259(1):62-71
C16	Goldberg et al., 1990, "Survey of exposure to genotoxic agents in primary myelodysplastic syndrome: correlation with chromosome patterns and data on patients without hematological disease," <i>Cancer Res.</i> 50(21):6876-6881
C17	Greenberg et al., 1997, "International scoring system for evaluating prognosis in myelodysplastic syndromes," <i>Blood</i> 89(6):2079-2088
C18	Gupta et al., 2001, "Adherences of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications," <i>Leukemia</i> 15:1950-1961
C19	Handman et al., 1979, "Stimulation by granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages," <i>J. Immunol.</i> 122(3):1134-1137
C20	Harris et al., 1999, "World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997," <i>J. Clin. Oncol.</i> 17(12):3835-3849
C21	Hellstrom et al., 1990, 76(Supp. 1):279a
C22	Koch, 1985, "Thalidomide and congeners as anti-inflammatory agents," <i>Prog. Med. Chem.</i> 22:165-242
C23	Kropff, 2000, <i>Blood</i> 96(11 part 1):168a
C24	Kurland et al., 1979, "Induction of prostaglandin E synthesis in normal and neoplastic macrophages: role for colony-stimulating factor(s) distinct from effects on myeloid progenitor cell proliferation," <i>Proc. Natl. Acad. Sci. USA</i> 76(6):3226-3230



C25	Lentzsch et al., 2003, "Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo," <i>Leukemia</i> 17(1):41-44
C26	List, 2002, ASH Abstract #521
C27	Marriott et al., 2001 "Immunotherapeutic and antitumour potential of thalidomide analogues," <i>Expert Opin. Biol. Ther.</i> 1(4):675-682
C28	McCann, 1999, <i>Drug Topics</i> pp. 41-42 (June 21, 1999)
C29	<i>The Merck Manual</i> , 1999, 17 th ed., pp. 953-955
C30	Metcalf, 1985, "The granulocyte-macrophage colony-stimulating factors," <i>Science</i> 229(4708):16-22
C31	Moller et al., 1997, "Inhibition of IL-12 production by thalidomide," <i>J. Immunol.</i> 159(10):5157-5161
C32	Moore, 1991, "The clinical use of colony stimulating factors," <i>Ann. Rev. Immunol.</i> 9:159-191
C33	Moore et al., 1980, "Production of lymphocyte-activating factor (Interleukin 1) by macrophages activated with colony-stimulating factors," <i>J. Immunol.</i> 125(3):1302-1305
C34	Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," <i>Bioorg. Med. Chem. Lett.</i> 9(11):1625-1630
C35	Muller et al., 1998, "Thalidomide analogs and PDE4 inhibition," <i>Bioorg. Med. Chem. Lett.</i> 8(19):2669-2674
C36	Muller et al., 1996, "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity," <i>J. Med. Chem.</i> 39(17):3238-3240
C37	Munshi et al., 1999, <i>Blood</i> 94(10 part 1):578a
C38	Ogawa, 1989, "Hemopoietic stem cells: stochastic differentiation and humoral control of proliferation," <i>Environ. Health Perspect.</i> 80:199-207
C39	Payvandi et al., 2003, ASCO Abstract #992
C40	Penichet et al., 2001, "Antibody-cytokine fusion proteins for the therapy of cancer," <i>J. Immunol. Methods.</i> 248(1-2):91-101
C41	<i>Physicians' Desk Reference</i> , 2002, 56 th ed. pp. 582-592, 1154-1158, 1755-1760
C42	Raza et al., 2001, "Thalidomide Produces Transfusion Independence in Long-standing Refractory Anemias of Patients with Myelodysplastic Syndromes," <i>Blood</i> 98(4):958-965
C43	Schrader et al., 1981, "The persisting (P) cell: histamine content, regulation by a T cell-derived factor, origin from a bone marrow precursor, and relationship to mast cells," <i>Proc. Natl. Acad. Sci. USA</i> 78(1):323-327
C44	Schuster et al., 1990, <i>Blood</i> 76(Supp. 1):318a
C45	Singhal et al., 1999, "Antitumor activity of thalidomide in refractory multiple myeloma," <i>N. Engl. J. Med.</i> 341(21):1565-1571
C46	Stanley et al., 1976, "Factors regulating macrophage production and growth: identity of colony-stimulating factor and macrophage growth factor," <i>J. Exp. Med.</i> 143(3):631-647
C47	Tabbara et al., 1991, "Hematopoietic growth factors," <i>Anticancer Res.</i> 11(1):81-90
C48	Vadas et al., 1983, "Eosinophil activation by colony-stimulating factor in man: metabolic effects and analysis by flow cytometry," <i>Blood</i> 61(6):1232-1241
C49	Vadas et al., 1983, "Activation of antibody-dependent cell-mediated cytotoxicity of human neutrophils and eosinophils by separate colony-stimulating factors," <i>J. Immunol.</i> 130(2):795-799
C50	Vasiliauskas et al., 1999, "An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease," <i>Gastroenterology</i> 117(6):1278-1287
C51	Weisbart et al., 1986, "Biosynthetic human GM-CSF modulates the number and affinity of neutrophil f-Met-Leu-Phe receptors," <i>J. Immunol.</i> 137(11):3584-3587
C52	Wolff, ed., 1995, <i>Burger's Medicinal Chemistry and Drug Discovery</i> , 5 th ed., pp. 172-178, 949-982

EXAMINER		DATE CONSIDERED	2/10/05
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

EXPRESS MAIL NO. EV452773474US



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO. 9516-072-999	APPLICATION NO. 10/411,649
APPLICANT Jerome B. Zeldis	
FILING DATE April 11, 2003	GROUP 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

W	C55	N. AKE JONNSON, 1972, "CHEMICAL STRUCTURE AND TERATOGENIC PROPERTIES," ACTA PHARM., PP. 521-542

EXAMINER	DATE CONSIDERED 2/10/05
----------	-------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.